December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Chandler Park’s Insights on the SunRISe Program and the Potential of TAR-200 for High-Risk Bladder Cancer
Nov 7, 2024, 00:11

Chandler Park’s Insights on the SunRISe Program and the Potential of TAR-200 for High-Risk Bladder Cancer

Chandler Park, Kentucky Physician Representative at ASCO State Executive Council, shared a post by Topline Bio on LinkedIn:

”Appreciate Topline Bio for the opportunity to discuss our practice changing SunRISe Bladder Cancer study.

Thank you to all of our patients that have enrolled in this study in Louisville, Kentucky.

Also grateful for the outstanding leadership of Ryan Malone, First Urology PSC and Norton Cancer Insitute for coming together on this research project.

Our team is honored to be the highest enrollers in the United States of America.”

Quoting Topline Bio‘s post:

”Listen in to Chandler Park‘s colorful Topline Take on the SunRISe program and the potential of of the investigational TAR-200 for patients with high-risk non-muscle-invasive bladder cancer as an innovative targeted release system.

We thank Park for his passion and commitment to patient care.”

Chandler Park, MD, FACP is an haematologist oncologist, medical journalist, and clinical researcher. He is the Advisory Dean and Clinical Professor at University of Louisville School of Medicine. He is the Kentucky Physician Representative of the ASCO State Executive Council. He is also the Medical Oncology Board Examiner at American Board of Internal Medicine.